Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3326
Motorsport Games
MSGM
$23.4M
| $84.7K | ﹤0.01% |
+29,200
| New | +$69.2K |
2025 Q2
0 quarters
|
|
3327
Skillful Craftsman
EDTK
$15.2M
| $83.7K | ﹤0.01% |
96,700
-13,900
| -13% | -$13.4K |
2021 Q2
16 quarters
|
|
|
RBOT
3328
DELISTED
Vicarious Surgical
RBOT
| $83.5K | ﹤0.01% |
11,134
-1,500
| -12% | -$10.9K |
2024 Q3
3 quarters
|
|
3329
KALA BIO
KALA
$5.75M
| $82.8K | ﹤0.01% |
+348
| New | +$67.9K |
2025 Q2
0 quarters
|
|
3330
CVRx
CVRX
$42.6M
| $82.3K | ﹤0.01% |
+14,000
| New | +$96.6K |
2025 Q2
0 quarters
|
|
|
GRCE
3331
Grace Therapeutics
GRCE
$43.1M
| $82K | ﹤0.01% |
27,625
-14,556
| -35% | -$38.7K |
2024 Q3
3 quarters
|
|
3332
VistaGen Therapeutics
VTGN
$10.6M
| $81K | ﹤0.01% |
40,500
+15,700
| +63% | +$35.7K |
2024 Q1
5 quarters
|
|
|
YQ
3333
17 Education & Technology Group
YQ
$32.4M
| $80.7K | ﹤0.01% |
36,830
+15,600
| +73% | +$30.2K |
2021 Q3
15 quarters
|
|
3334
Coya Therapeutics
COYA
$117M
| $80.5K | ﹤0.01% |
14,000
+1,800
| +15% | +$10.4K |
2025 Q1
1 quarter
|
|
|
IMDX
3335
Insight Molecular Diagnostics
IMDX
$107M
| $78.8K | ﹤0.01% |
+26,100
| New | +$78.9K |
2025 Q2
0 quarters
|
|
|
SBFM
3336
Sunshine Biopharma
SBFM
$1.45M
| $77.9K | ﹤0.01% |
+5,409
| New | +$79K |
2025 Q2
0 quarters
|
|
3337
ClearOne Inc
CLRO
$11M
| $77.3K | ﹤0.01% |
13,447
-1,081
| -7% | -$7.52K |
2013 Q2
48 quarters
|
|
|
SOHO
3338
DELISTED
Sotherly Hotels
SOHO
| $76.7K | ﹤0.01% |
80,714
+200
| +0.2% | +$158 |
2014 Q3
43 quarters
|
|
3339
Alto Neuroscience
ANRO
$959M
| $76.3K | ﹤0.01% |
+34,700
| New | +$82.6K |
2025 Q2
0 quarters
|
|
3340
Urban One Class A
UONE
$19.8M
| $75.5K | ﹤0.01% |
4,720
+10
| +0.2% | +$155 |
2021 Q4
14 quarters
|
|
|
PCLA
3341
PicoCELA Inc
PCLA
$63.5M
| $74K | ﹤0.01% |
+1,523
| New | +$34K |
2025 Q2
0 quarters
|
|
3342
Armata Pharmaceuticals
ARMP
$142M
| $73.9K | ﹤0.01% |
38,896
+300
| +0.8% | +$486 |
2017 Q2
32 quarters
|
|
3343
Elutia
ELUT
$37M
| $73.3K | ﹤0.01% |
37,016
-700
| -2% | -$1.42K |
2023 Q1
9 quarters
|
|
3344
Wrap Technologies
WRAP
$87.7M
| $73K | ﹤0.01% |
+46,800
| New | +$70.5K |
2025 Q2
0 quarters
|
|
|
LONA
3345
LeonaBio Inc
LONA
$54.7M
| $72.8K | ﹤0.01% |
24,100
+2,200
| +10% | +$6.23K |
2022 Q3
11 quarters
|
|
3346
Performance Shipping
PSHG
$20.6M
| $72.8K | ﹤0.01% |
41,584
+13,184
| +46% | +$20.7K |
2023 Q3
7 quarters
|
|
|
SOGP
3347
Sound Group
SOGP
$44.1M
| $72K | ﹤0.01% |
15,158
| – | – |
2021 Q2
16 quarters
|
|
|
INCR
3348
Intercure
INCR
$75.5M
| $71.9K | ﹤0.01% |
9,780
+100
| +1% | +$739 |
2023 Q1
9 quarters
|
|
3349
Atlantic American Corp
AAME
$24.3M
| $71.1K | ﹤0.01% |
33,400
+300
| +0.9% | +$502 |
2013 Q2
48 quarters
|
|
3350
Grove Collaborative
GROV
$45.3M
| $70.8K | ﹤0.01% |
61,600
+5,200
| +9% | +$6.15K |
2024 Q2
4 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.